Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy, talking with David Townsend, PhD, and Thomas Beyer, PhD, MBA, about their pioneering work in development of PET/CT technology.
Page 1541
Improving TRT approaches: Chan and colleagues present a state-of-the-art review of combination strategies with targeted radionuclide therapy as reported in the literature and describe the associated therapeutic potential.
Page 1544
Imaging the cancer immune environment: Iravani and Hicks continue an educational overview of immune environment oncologic monitoring with PET, looking beyond 18F-FDG PET to novel agents and suggesting an algorithm for evaluation and integration into routine practice.
Page 1553
18F-FDG PET/CT and PRRT prognosis: Zhang and colleagues report on the predictive role of 18F-FDG PET/CT in a large cohort of patients with metastatic neuroendocrine neoplasms treated with peptide-receptor radionuclide therapy, including long-term follow-up.
Page 1560
Total-lesion volume and glycolysis: Reynolds and colleagues explore the implications of tumor metabolic and volume metrics as assessed on 18F-FDG PET in patients with malignant pleural mesothelioma.
Page 1570
68Ga-PSMA-11 for colorectal cancer: Cuda and colleagues image patients with metastatic colorectal cancer to assess the tumor avidity of this prostate-specific membrane antigen–targeting agent to inform decision making in peptide-receptor radionuclide therapy.
Page 1576
First-in-humans trial of 18F-SKI-249380: Krebs and colleagues detail the results of whole-body PET/CT imaging with this dasatinib-derivative imaging agent in patients with prior diagnoses of breast cancer, renal cell cancer, or leukemia.
Page 1580
PDT of GLP-1R–positive lesions: Boss and colleagues describe a novel method for therapy of hyperinsulinemic hyperglycemia, selectively killing β-cells by receptor-targeted photodynamic therapy with exendin-4-IRDye 700DX, targeting the glucagonlike peptide 1 receptor.
Page 1588
89Zr-BiTE molecules: Suurs and colleagues explore the pharmacokinetic characteristics and immune cell roles of radiolabeled bispecific T-cell engager molecules in immunocompetent and immunodeficient mouse models.
Page 1594
Neuroendocrine differentiation and RLT: Derlin and colleagues investigate the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen–targeted radioligand therapy.
Page 1602
68Ga-PSMA–guided bone biopsies: de Jong and colleagues determine the success rate of 68Ga-prostate-specific membrane antigen–guided bone biopsies for molecular diagnostics in patients with metastatic prostate cancer.
Page 1607
Partial-volume effect on PSMA uptake: Ortega and colleagues research the effect of a smoothing filter and partial-volume correction on 18F-DCFPyL PET/CT–measured prostate-specific membrane antigen activity in small metastatic lesions and resulting changes on PSMA molecular imaging scoring.
Page 1615
TSPO radioligand data pooling in ALS: Van Weehaeghe and colleagues ask whether data pooling of different translocator protein radioligands is feasible for use in multicenter pharmacodynamic biomarker analyses in amyotrophic lateral sclerosis trials.
Page 1621
Quantification of 123FP-CIT SPECT in DLB: Maltais and colleagues describe the results of a retrospective study comparing 3 123FP-CIT SPECT quantitative methods in patients with neurodegenerative syndromes and compare with neuropathologic findings.
Page 1628
Kinetic analysis of novel κ-agonists: Naganawa and colleagues assess in humans the kinetics, binding properties, and test–retest reproducibility of 2 11C-labeled κ-opioid receptor agonist radiotracers for PET imaging.
Page 1636
Folate receptor imaging in myocarditis: Jahandideh and colleagues evaluate 18F-FOL PET for detection of myocardial inflammation in rats with autoimmune myocarditis and study the expression of folate receptor β in human cardiac sarcoidosis specimens.
Page 1643
Lung ABCC1 activity: Mairinger and colleagues detail preclinical studies of PET imaging with pulmonary-administered 11C-BMP to measure multidrug resistance–associated protein ABCC1 activity at the lung epithelial barrier and describe potential clinical applications.
Page 1650
Radiobiological dosimetry for SIRT: Abbott and colleagues report on establishment of dose–response relationships for selective internal radiation therapy in patients with metastatic colorectal cancer when informed by radiobiologic sensitivity parameters derived from mCRC cell lines exposed to 90Y.
Page 1658
11C-PABA PET renal imaging: Ruiz-Bedoya and colleagues explore in both preclinical and first-in-humans studies the hypothesis that 11C-labeled para-aminobenzoic acid may allow high-quality dynamic PET of the kidneys with less radiation exposure.
Page 1665
Phosphodiesterase type 4 PET in MAS: Weidner and colleagues investigate the potential of PET imaging with 11C-(R)-rolipram to indirectly measure and elucidate the mechanisms of increased 3′,5′-cyclic adenosine monophosphate pathway activation in patients with McCune–Albright syndrome.
Page 1672
Data- versus device-based gating: Walker and colleagues compare the performance of a recently commercialized data-driven method for respiratory gating with that of an external, device-based system for oncologic 18F-FDG PET/CT imaging.
Page 1678
Lesion detectability with digital PET: Surti and colleagues report on a lesion detectability investigation of 2 generations of Biograph PET/CT scanners, the mCT Flow and the Vision, to study the impact of improved physical performance on clinical performance.
Page 1684
- © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.